Floatz logo

Neflamapimod

Lewy Body Dementia

EIP Pharma IncSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Lewy Body Dementia cohort.

Asset / SponsorPhaseRating
Memantine
Zealand University Hospital
Phase 4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Virginia Commonwealth University
Phase 4BB
Sitagliptin
Mayo Clinic
Phase 4BB
Dapagliflozin
Mayo Clinic
Phase 4BB
Armodafinil
NYU Langone Health
Phase 4BB

View all 49 →

Same molecule, other indications

Neflamapimod is also rated in:

Alzheimer diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →
cognitive disorderDormant
CCC
Indicative · Phase 2
54 / 100
View asset →
progressive non-fluent aphasiaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →